United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,234 shares of the stock in a transaction on Thursday, July 6th. The shares were sold at an average price of $132.29, for a total value of $163,245.86. Following the sale, the chief executive officer now owns 1,374 shares of the company’s stock, valued at approximately $181,766.46. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Shares of United Therapeutics Corporation (NASDAQ:UTHR) traded down 0.08% during mid-day trading on Monday, hitting $130.95. The company had a trading volume of 442,519 shares. United Therapeutics Corporation has a one year low of $108.40 and a one year high of $169.89. The firm’s 50-day moving average price is $126.51 and its 200 day moving average price is $138.49. The company has a market capitalization of $5.90 billion, a P/E ratio of 9.19 and a beta of 1.52.
United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, April 26th. The biotechnology company reported $3.89 EPS for the quarter, beating the consensus estimate of $3.12 by $0.77. The business had revenue of $370.50 million for the quarter, compared to analysts’ expectations of $399.59 million. United Therapeutics Corporation had a net margin of 41.04% and a return on equity of 34.74%. The firm’s revenue was up .4% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.02 EPS. Analysts predict that United Therapeutics Corporation will post $14.46 earnings per share for the current fiscal year.
A number of brokerages have recently commented on UTHR. Credit Suisse Group began coverage on United Therapeutics Corporation in a research report on Thursday, March 16th. They set an “underperform” rating and a $120.00 price objective for the company. Jefferies Group LLC reiterated an “underperform” rating and set a $116.00 price objective on shares of United Therapeutics Corporation in a research report on Friday, March 17th. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of United Therapeutics Corporation in a research report on Monday, April 3rd. UBS AG reiterated a “sell” rating and set a $106.00 price objective on shares of United Therapeutics Corporation in a research report on Thursday. Finally, BidaskClub upgraded United Therapeutics Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 16th. Four investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. United Therapeutics Corporation currently has a consensus rating of “Hold” and an average target price of $134.50.
Large investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in United Therapeutics Corporation by 4,222.8% in the first quarter. BlackRock Inc. now owns 4,741,985 shares of the biotechnology company’s stock valued at $641,969,000 after buying an additional 4,632,287 shares in the last quarter. Norges Bank bought a new stake in United Therapeutics Corporation during the fourth quarter valued at approximately $63,975,000. AQR Capital Management LLC boosted its stake in United Therapeutics Corporation by 27.8% in the first quarter. AQR Capital Management LLC now owns 1,736,357 shares of the biotechnology company’s stock valued at $235,068,000 after buying an additional 377,395 shares in the last quarter. Vanguard Group Inc. boosted its stake in United Therapeutics Corporation by 7.3% in the first quarter. Vanguard Group Inc. now owns 3,785,099 shares of the biotechnology company’s stock valued at $512,427,000 after buying an additional 256,514 shares in the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in United Therapeutics Corporation by 142.6% in the first quarter. BNP Paribas Arbitrage SA now owns 365,204 shares of the biotechnology company’s stock valued at $49,441,000 after buying an additional 214,687 shares in the last quarter.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2286350/united-therapeutics-corporation-nasdaquthr-ceo-martine-a-rothblatt-sells-1234-shares.html
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.